Business
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for
About this update from Annexon, Inc.
[{"type":"text","content":"BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. “We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (GBS) and geographic atrophy (GA),” said Douglas Love, president and chief executive officer of Annexon. “Attracting strong talent with extensive experience in developing winning product strategies and leading some of the most successful immunology product launches to-date is a win. These leaders will help Annexon to realize the significant market opportunities for our first-in-kind product candidates and allow us to achieve our mission of aiding millions of patients that are impacted by devastating neuroinflammatory diseases.” Shikhar Agarwal, M.B.A. is a seasoned leader with over 20 years in pharmaceutical marketing, market access, sales and commercial operations, and a track record of successfully leading portfolio strategy, organization build and product launch execution across therapeutic areas. Prior to joining Annexon, he was vice president, head of marketing at argenx SE, where he led the launch of VYVGART® in Myasthenia Gravis and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), delivering $400 million in first year revenue and achieving blockbuster status in second year of launch amidst multiple competitive launches. Prior to that he held commercial roles of increasing responsibility at Amgen Inc. across market access, marketing, sales and market research. Early in his career, he worked as a senior consultant at Proxicom, Inc., where he developed commercial and analytical solutions for Fortune 500 clients. Mr. Agarwal holds an M.B.A. from UCLA Anderson School of Management, and a B.S. from St. John’s College in Agra, India. Sunil B. Mehta, Pharm.D. brings 20 years of medical affairs experience including successfully bu...